Smarter Studies. Global Impact. Better Health.
The MRC Clinical Trials Unit (MRC CTU) at UCL is at the forefront of resolving internationally important questions in infectious diseases and cancer, and delivering swifter and more effective translation of scientific research into patient benefits.
Latest News and Updates
MRC CTU at UCL contributes to clinical trial capacity- and capability-building in India
A number of MRC CTU at UCL staff have been in India over the last two months contributing to capacity and capability building as part of the Units efforts to strengthen the country’s clinical research ecosystem. The focu…
STREAM trial final results show 9-month treatment for multi-drug resistant TB is as effective as 24-month treatment
Final results from Stage 1 of the STREAM trial show that a 9-11-month treatment regimen is as effective in treating multidrug-resistant tuberculosis (MDR-TB), when given under trial conditions, as the 20-24 month treatme…
Adult dolutegravir could offer a practical and accessible treatment for children living with HIV
Adult doses of an antiviral drug could offer a practical and accessible option for children weighing 20-25kg living with HIV.
Radiotherapy to the prostate should be considered for men with low metastatic burden, hormone-sensitive prostate cancer
Research has found that prostate radiotherapy should be considered for men with hormone sensitive prostate cancer (mHSPC) whose disease has not spread too much beyond the prostate at diagnosis. These results are the late…
Our Research Themes
Cancer
Innovative clinical trial design and meta-analysis extending beyond the boundaries of single cancer types
Infections
Major international clinical trials answering questions of global public health significance
Methodology
Development of methods with direct impact on the design, conduct and analysis of studies
Our Latest Tweets
-
#STAMPEDEtrial shows that prostate radiotherapy improves survival for men with low burden metastatic #ProstateCancer, but not high burden. Watch our animated abstract to learn more: https://t.co/0WC2yCU05W @Prof_Nick_James @PCaParker @mattsydes @ProstateUKProfs @ProstateUK https://t.co/2IOEcymJmd
-
#Publication - Optimising the diagnosis of prostate cancer in the era of multiparametric magnetic resonance imaging: A cost-effectiveness analysis based on the prostate MR imaging study (PROMIS). https://t.co/ytd6JlK1SW https://t.co/VgaIwE1S4M
-
#Publication - Here's the 🔓 open-access link to the STAMPEDE metastatic radiotherapy paper in @TheLancet https://t.co/HqvDsLKFWc @PCaParker @Prof_Nick_James @mattsydes https://t.co/0pDkpPg8UQ
